Last reviewed · How we verify
Anti-MRSA therapy
Targets bacterial cell wall synthesis to inhibit MRSA growth.
Targets bacterial cell wall synthesis to inhibit MRSA growth. Used for Treatment of complicated urinary tract infections caused by MRSA.
At a glance
| Generic name | Anti-MRSA therapy |
|---|---|
| Also known as | Anti-MRSA Antibiotics |
| Sponsor | Methodist Health System |
| Drug class | Betalactamase inhibitor |
| Target | Bacterial cell wall synthesis enzyme |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
This drug works by inhibiting the enzyme responsible for cell wall synthesis in MRSA bacteria, ultimately leading to bacterial cell death. This mechanism of action is specific to bacterial cell wall synthesis and is not effective against other types of bacteria or viruses.
Approved indications
- Treatment of complicated urinary tract infections caused by MRSA
Common side effects
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
- A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients (PHASE4)
- Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia (PHASE4)
- Rapid De-escalation of Anti-MRSA Therapy Guided by S. Aureus Nares Screening in Case of Pneumonia (NA)
- Comparative Analysis of Nemonoxacin and Other Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA) Antimicrobial Therapy in Patients With Complicated Skin and Soft Tissue Infections (cSSTI): a Retrospective Chart Review Study
- Initial Oral Antibiotics for Bone and Joint Infections in Children
- Don't Treat Ghosts Anti-MRSA Antibiotics in Osteomyelitis Without Identified MRSA
- GRam Stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) Trial (PHASE4)
- Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-MRSA therapy CI brief — competitive landscape report
- Anti-MRSA therapy updates RSS · CI watch RSS
- Methodist Health System portfolio CI